Details of the Drug
General Information of Drug (ID: DMS325C)
| Drug Name |
6-fluoropyridin-3-ylboronic acid
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
351019-18-6; 2-Fluoropyridine-5-boronic acid; 2-Fluoro-5-pyridylboronic acid; (6-fluoropyridin-3-yl)boronic Acid; 6-fluoropyridine-3-boronic acid; 2-fluoro-5-pyridineboronic acid; 2-fluoropyridin-5-ylboronic acid; 6-fluoropyridin-3-ylboronic acid; 2-fluoropyridin-5-boronic acid; 6-Fluoro-3-pyridinylboronic acid; 6-Fluoro-3-pyridylboronic Acid; 6-fluoropyridin-3-yl-3-boronic acid; 6-FLUORO-3-PYRIDINEBORONIC ACID; (6-fluoropyridin-3-yl)boranediol; BORONIC ACID, (6-FLUORO-3-PYRIDINYL)-; (6-fluoro-3-pyridyl)boronic acid
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 140.91 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


